By Sandra Silvestri, EVP & Chief Medical Officer, Ipsen
In today’s rapidly evolving treatment landscape the approval of a medicine is no longer the finish line; it’s just the beginning. Real world evidence (RWE), post-hoc analyses and structured Phase IV studies all offer new opportunities for scientific learning. At Ipsen, we’re committed to pursuing the unanswered questions, generating robust evidence that goes beyond medicine development, which provides broader long-term evidence-based perspectives for the communities we serve.
The expanding role of RWE
Clinical trials answer essential scientific questions, but by design, they can never fully capture the reality of people’s everyday lives—the diversity of experiences, the complexity of conditions, and the unpredictability of care journeys.
RWE helps bridge that gap. It reflects what really matters to people: how well a medicine works over time, how tolerable it is day-to-day, and how it fits into the realities of living with a condition. By investing in robust RWE, we are deepening our understanding of patients’ needs, capturing the genuine impact of our medicines and ensuring they continue to deliver meaningful benefits for the people who rely on them.
Post-hoc analyses and Phase IV trials: deepening insight where it matters most
Post hoc analyses and Phase IV studies, conducted after a medicine is approved, play an equally important role. Directed by the diversity of patients and the often-varied care pathways, we explore assumptions to generate insights in the context of real-world challenges. How do our medicines impact patients with certain comorbidities or receiving other medications? What other markers may be clinically relevant to investigate? How has the treatment landscape and in turn, treatment guidelines evolved? By taking a focused approach, we’re designing analyses to answer the most pressing topics for clinicians and patients, enriching understanding and supporting more individualized care.
A future defined by continuous learning
Real world insights combined with the depth of Phase IV trials and post-hoc analyses, offer a powerful, multidimensional understanding of a medicine’s impact. For Ipsen, data generation post approval is not an add on, it is a commitment. A commitment to truly understand the impact of our medicines, not just for the many but for the unique individuals who deserve answers.
The future of patient care will depend on this continuous learning mindset. Approval is a milestone worth celebrating, but it is not the end. Every real-world insight, every long-term outcome, every post-approval analysis brings us closer to optimizing care for the people who need it most. Our goal is clear: to ensure that scientific progress does not stop at approval but accelerates through it so that every patient receives not only an innovative medicine, but one that evolves with evidence, precision and purpose.
ALLSC-GB-001488
July 2026
At Ipsen, medical insights are not an end in themselves. They help us better understand the reality experienced by patients, healthcare professionals and health systems so we can make better decisions across our organisation.
This matters because quality insights can lead to clear and focused action: shaping evidence generation, informing medical strategy, strengthening cross-functional decision-making and helping Ipsen respond more effectively to unmet needs. At the heart of this approach is a simple principle: curiosity and active listening can help us act for patients and society.
This reflects Ipsen’s broader strategy: a science-led, patient-driven approach that turns knowledge into enterprise-wide impact. By embedding patient insights and robust data into decision-making, Medical helps connect what we learn through scientific engagement to the strategic choices that shape our evidence plans and portfolio priorities across Oncology, Rare Disease and Neuroscience. This ensures that, as we advance our pipeline and strengthen our portfolio, patient needs remain central to how we create value, guide investment and deliver meaningful impact for the communities we serve.
To make this work in practice, Ipsen focuses on four connected capabilities:
Structured insight generation
aligned to quality standards, to bring the right capabilities in curiosity and listening for insights and to capture what matters most and connect evidence to strategic priorities.
Strong governance and prioritisation
to ensure insights are synthesised, assessed and acted on by the right teams.
Digital, analytical and AI-enabled capabilities
to identify patterns faster and support more informed decisions.
Cross-functional activation
so insights can shape action across Medical, R&D and beyond.
“When insights are brought together systematically across markets and therapeutic areas, they can help identify shared needs, guide evidence generation priorities and strengthen alignment across functions and geographies. In this way, global strategy is informed not only by data, but by a clearer understanding of what matters most in practice.”
“Insights have the greatest value when they help teams respond to the realities of their healthcare environment – whether by refining engagement, informing local evidence needs or improving collaboration across functions. This is how strategy becomes more grounded, more relevant and ultimately more useful for the communities Ipsen serves.”
Together, these perspectives show that elevating medical insights is not simply about gathering more information. It is about creating the conditions for insight to become action – through shared ownership, clear priorities and a commitment to using what we learn to improve decision-making for patients.
As Ipsen continues to expand our portfolio at every stage of development, turning insights into action will remain essential to how we work. It helps us listen more effectively, learn more systematically and act with greater focus across global and local settings.
Because at Ipsen, the value of insight lies in what it helps us do: make better decisions, work better together and create greater impact for patients.
ALLSC-GB-001481
July 2026
By Christelle Huguet, EVP & Head of R&D, Ipsen
For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.
At the heart of this transformation lie biomarkers. What mutations are driving disease progression? How do tumor cells distinguish themselves from healthy cells? And importantly, how can these biological signatures guide us to the people with the highest unmet need? The ability to answer these questions allows us to focus our efforts on the most compelling science—science with purpose.
However, biomarkers are only one part of the story. As we unlock deeper insights into disease mechanisms, we must also equip ourselves with the right tools to act on them. That is why Ipsen is building a multimodality R&D engine, grounded in precision immune‑modulation and our expertise in the intracellular signalling pathway. Each modality is designed with purpose: to act on well‑defined biology as an innovative or first‑in‑class medicine.
What makes this progress truly powerful is its real‑world impact on patients. It opens doors to more targeted, and potentially more effective, options. But it’s equally important to recognize where the pathophysiology drivers are less clear and more work is required. Many cancers lack clear biomarkers, and too many patients continue to face conditions that remain under researched or poorly understood. This is exactly why we must continue to push the boundaries of innovation—so that scientific progress translates into real change.
At Ipsen, our ambition is clear: to develop a pipeline defined not by the limits of traditional medicine development, but by the possibilities of precision. Precision medicine is not a new concept—it is here, reshaping what we can deliver for patients today and redefining what will be possible for generations to come. And as science advances, we will continue to act with agility, focus and purpose to turn breakthrough insights into real solutions for the people who need them most.
ALLSC-GB-001382
May 2026